| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Filing example | IND | — | Subscribe to access the data. | Small Molecules | Oncology | ||
IND Filing example | IND | — | Subscribe to access the data. | Small Molecules | Oncology | ||
IND Filing example | IND | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Foghorn Therapeutics Inc.$5.95
-0.06 (-1%)
D 39Pipeline Score Overvalued Biotech · Commercial
Market Cap
247.77 M
EPS
-1.20
P/E Ratio
-
Value Trade
521.59 K
SEC Financials
Q1 2026Dilution Risk
Revenue
3.27 M
R&D Expenses
18.26 M
Operating CF
-25.27 M
Total Assets
222.17 M
Total Liabilities
298.57 M
Equity
-76.41 M
D/E Ratio
12,345
4.71 %
Week
-19.16 %
1 Month
-26.86 %
3 Month
-8.06 %
6 Month
-57.97 %
5 Year
-77.79 %
All Time
Cash Data
Cash Position
183.63 M
Monthly Burn
8.42 M
Runway
19.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
293.94 K
52 Week Range
3.27 - 6.95
% held by Insiders
47.28 %
% held by Institutions
42.79 %
Enterprise Value
104.89 M
Total Shares
58.72 M
Short %
4.5 %
Float Shares
33.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Foghorn Therapeutics Inc.
343Total events
8Upcoming
40Tier-1 (high impact)
2020 – 2028Coverage
Upcoming catalysts 8
Event history 335
Jun 9, 2026
◆Oral PresentationPresentation
Fireside Chat at Goldman Sachs 47th Annual Global Healthcare Conference 2026
May 26, 2026
◆Oral PresentationPresentation
Foghorn management to present at TD Cowen 7th Annual Oncology Innovation Summit
May 20, 2026
◆Oral PresentationPresentation
Foghorn management to present at 2026 Stifel Virtual Targeted Oncology Forum
May 19, 2026
◆Oral PresentationPresentation
Foghorn management to participate in one-on-one meetings at H.C. Wainwright 4th Annual Bioconnect Investor Conference
May 7, 2026
▲Enrollment UpdateFHD-909Trial
Phase 1 trial enrollment progressing well and on track
SMARCA4-mutant non-small cell lung cancersource ↗
May 7, 2026
Apr 22, 2026
◆Oral PresentationPresentation
Oral presentation on towards new cancer medicines with degraders of chromatin regulatory proteins
cancersource ↗
Apr 22, 2026
◆Poster PresentationFHT-171Presentation
Poster presentation on preclinical characterization of FHT-171, a first-in-class degrader targeting CBP
CBP-dependent solid tumorssource ↗
Apr 21, 2026
◆Oral PresentationFHD-909Presentation
Oral presentation on leveraging paralog relationships for targeting chromatin modulators in cancer: ARID1B and SMARCA2 (FHD-909)
SMARCA4-mutant cancerssource ↗
Apr 21, 2026
▲Oral PresentationEP300Presentation
Oral presentation at AACR 2026: Targeting chromatin regulatory proteins in hematologic malignancies (EP300 degrader)
multiple myelomasource ↗
Apr 21, 2026
▲Poster PresentationFHT-171Presentation
Poster presentation at AACR 2026: Preclinical characterization of FHT-171, a first-in-class degrader targeting CBP
CBP-dependent solid tumors (ER+ breast cancer)source ↗
Drug Pipeline Intelligence
D39
Pipeline Score $79M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.3x
rNPV / MCap Top 55%
Micro Cap (rank 411 of 911)
Percentile RankFoghorn Therapeutics Inc. faces pipeline headwinds (39/100), with $587M risk-adjusted pipeline value, led by FHD-286 in Small Cell Lung Cancer (Phase 2), across $105B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FHD-286 Small molecule | Small Cell Lung Cancer | Phase 2 | NCT07551635 | 10% | $557M | NOT YET_RECRUITING | 20 | - | - | Jan 31, 2029 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
FHD-286 | relapsed and refractory AML | Phase 1 | 2024-12-16 | objective clinical responses were observed by standard response criteria Read More | Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in co Read More | |
FHD-286 | relapsed and refractory AML | Phase 1 | 2024-12-16 | objective clinical responses were observed by standard response criteria Read More | Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in co Read More | |
FHD-286 | relapsed and refractory AML | Phase 1 | 2024-12-16 | objective clinical responses were observed by standard response criteria Read More | Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in co Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FHTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
FHTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
FHTXFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Foghorn Therapeutics Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The company, focused on advancing gene expression correction technologies, will feature a fireside chat by CEO Adrian Gottschalk on June 9, 2026. Additionally, Foghorn will engage in one-on-one meetings at the event. The conference highlights Foghorn's commitment to addressing serious diseases, particularly in oncology.
Read more →FHTXFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
Foghorn Therapeutics Inc. will participate in three investor conferences in May 2026, including the H.C. Wainwright 4th Annual Bioconnect Investor Conference and the TD Cowen 7th Annual Oncology Innovation Summit. CEO Adrian Gottschalk will present at the Stifel Virtual Targeted Oncology Forum and the Cowen Summit, highlighting the company's innovative approach to oncology through its Gene Traffic Control platform.
Read more →FHTX▼ -10.3%on this newsshared move
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
Foghorn Therapeutics provided a financial and corporate update, highlighting progress in its clinical trials, particularly FHD-909 for NSCLC patients with SMARCA4 mutations. The company reported promising preclinical data for its selective CBP and EP300 degraders, with IND filings anticipated in 2027. Despite a net loss increase, Foghorn maintains a strong financial position with substantial cash reserves.
Read more →FHTXFoghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Complete and durable regression and a
Foghorn Therapeutics presented new preclinical data at the 2026 AACR Annual Meeting, highlighting promising results for their Selective SMARCA2 inhibitor FHD-909 in combination with an anti-PD-1 antibody, demonstrating tumor regression and lasting immune memory in animal models. The data also showcased the efficacy and safety of their Selective CBP and EP300 degrader programs in treating difficult cancers. Notably, the Selective CBP degrader FHT-171 showed strong activity in heavily pretreated ER+ breast cancer, while EP300 degraders outperformed existing treatments in multiple myeloma. Overall, the presentations underscored Foghorn's advancements in developing targeted therapies for cancer.
Read more →FHTXFoghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics announced new preclinical data for its selective SMARCA2 inhibitor FHD-909 and degrader programs at the 2026 AACR Annual Meeting. The data suggests potential expansion opportunities for FHD-909 in combination with anti-PD-1 antibodies for treating SMARCA4-mutant lung cancer. Additionally, the company showcased progress in its selective CBP, EP300, and ARID1B degrader programs, highlighting their promise in treating challenging cancers.
Read more →FHTXFoghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell
Foghorn Therapeutics has provided a financial update alongside a strategic outlook for 2025 and 2026. The company highlighted the progress of its lead candidate, FHD-909, a treatment for SMARCA4-mutant non-small cell lung cancer, which is currently in Phase 1 trials. Additionally, Foghorn announced a successful $50 million financing round, significantly improving its financial position and extending operational runways. Upcoming IND-enabling studies for additional programs targeting various cancers are slated for 2026.
Read more →FHTXFoghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Foghorn Therapeutics Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference and The Citizens Life Sciences Conference. The company is focused on developing innovative treatments for serious diseases through its Gene Traffic Control platform. A webcast of the TD Cowen presentation will be available on their website for 90 days.
Read more →FHTXFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Foghorn Therapeutics has appointed Ryan Maynard as Chief Financial Officer, effective February 23, 2026. With over 25 years of experience in the biopharmaceutical sector, Maynard aims to enhance the company's financial strategy and operational performance. His previous roles include CFO at Cara Therapeutics, where he led significant financial transactions. His expertise is expected to support Foghorn's growth and development of novel therapies.
Read more →FHTXFoghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Foghorn Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026, in New York. The company focuses on developing innovative medicines to correct abnormal gene expression, particularly in oncology. A webcast of their presentation will be available for 30 days following the event.
Read more →FHTX▼ -5.5%on this news· ran to -17% by day 3
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Foghorn Therapeutics has successfully closed a $50 million registered direct financing at a 30% premium. The offering included the sale of over 2 million shares at $6.71 each, with additional warrants for future purchases. Key investors included BVF Partners and Deerfield Management. The funds will support the company's development of novel medicines targeting gene expression.
Read more →FHTXFoghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and
Foghorn Therapeutics has successfully raised $50 million in equity financing, which is expected to close on January 13, 2026. The funds will support ongoing development of its cancer treatment pipeline, including a Phase 1 trial of FHD-909 targeting SMARCA4-mutant non-small cell lung cancer. The company also highlighted progress in its Selective CBP and EP300 degrader programs, both of which are projected to be IND-ready in 2026. With a strong balance sheet showing $208.9 million in cash and equivalents, Foghorn aims to continue strategic investments in its therapeutic programs through at least the first half of 2028.
Read more →FHTX▲ +23.6%on this newsshared move
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Foghorn Therapeutics has announced a successful equity financing round, raising $50 million from prominent investors, which will bolster its pipeline development activities. The company's Phase 1 trial of FHD-909, targeting SMARCA4-mutant cancers, is moving forward as planned. Additionally, its Selective CBP and EP300 degrader programs are anticipated to be IND-ready by 2026. This financing positions Foghorn to extend its operational runway into mid-2028 while continuing to innovate in cancer treatment.
Read more →FHTXFoghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Foghorn Therapeutics will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Coral Gables, FL. The company's management will host a fireside chat on December 4 at 9:10 a.m. EST. Foghorn focuses on developing innovative treatments targeting gene expression abnormalities, particularly in oncology.
Read more →FHTX▲ +13.3%on this news· ran to +25% by day 3
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Foghorn Therapeutics provided a financial and corporate update for Q3 2025, highlighting the progress of its FHD-909 Phase 1 trial targeting SMARCA4-mutated cancers, particularly non-small cell lung cancer (NSCLC). The company reported a strong cash position of $180.3 million, ensuring operational stability into 2028. Additionally, Foghorn is advancing multiple selective degrader programs aimed at various cancers, although the departure of CFO Kristian Humer raises some concerns about leadership continuity.
Read more →FHTXFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics announced its participation in three upcoming investor conferences, including the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. The company focuses on developing innovative treatments for serious diseases through its Gene Traffic Control platform, particularly in oncology. Presentations will be available via webcast on their website.
Read more →FHTXFoghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
Foghorn Therapeutics has announced advancements in its Selective ARID1B, CBP, and EP300 degrader programs. The Selective ARID1B degrader has shown potential in treating various solid tumors, while the Selective CBP degrader is set for non-GLP toxicology studies in Q4 2025. The Selective EP300 degrader demonstrates efficacy in hematological malignancies, marking significant progress for the company.
Read more →FHTXFoghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
Foghorn Therapeutics has announced key updates regarding its Selective ARID1B degrader program, which will be presented at the 8th Annual TPD and Induced Proximity Summit. The findings suggest the program could become a new treatment option for patients with endometrial, gastric, and bladder cancers. Additionally, a virtual investor event will provide further insights into the company's ongoing projects.
Read more →FHTXFoghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary
Foghorn Therapeutics recently provided an update on its ongoing clinical projects and financial status for Q2 2025. The FHD-909 Phase 1 trial, focusing on SMARCA4 mutated cancers with non-small cell lung cancer as the primary target, is progressing well with strong patient enrollment. Additionally, preclinical data indicate promising synergistic effects when FHD-909 is combined with pembrolizumab and KRAS inhibitors. The company maintains a robust balance sheet with nearly $200 million, providing financial stability to advance its multiple oncology programs.
Read more →FHTXFoghorn Therapeutics to Participate in Four Upcoming Investor Conferences
Foghorn Therapeutics Inc. has announced its participation in four upcoming investor conferences, highlighting its Gene Traffic Control platform aimed at addressing serious diseases. CEO Adrian Gottschalk will represent the company during these events, including both presentations and one-on-one meetings. The conferences are aimed at increasing visibility among investors and showcasing its potential in oncology. The events will occur between May and June 2025 and will also be accessible via webcast on the company's website.
Read more →FHTX▼ -5.1%on this news
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as
Foghorn Therapeutics has provided an update on its financial status and ongoing clinical developments as of Q1 2025. The Phase 1 trial of FHD-909 (LY4050784), targeting SMARCA4 mutated cancers, is progressing well with promising preclinical data showcasing its synergistic potential with other therapies. The company maintains a strong financial position with substantial capital reserves, facilitating continued development of its innovative oncology programs. Additionally, new appointments to the Board of Directors have been made, enhancing the company's leadership capabilities.
Read more →FHTX▼ -8.5%on this news
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
Foghorn Therapeutics will participate in the Citizens Life Sciences Conference on May 7-8, 2025, in New York. CEO Adrian Gottschalk will present during a fireside chat and the management will hold one-on-one meetings. The company focuses on developing innovative treatments for serious diseases through its Gene Traffic Control platform.
Read more →FHTXFoghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
Foghorn Therapeutics has appointed Neil Gallagher, M.D., Ph.D., and Stuart Duty to its Board of Directors. Both bring extensive experience in biotechnology and finance, which the company aims to leverage to advance its pipeline of therapies targeting cancer. The appointments are seen as a strategic move to enhance Foghorn's capabilities in drug development.
Read more →FHTXFoghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - FHD-909 (LY4050784) advancing in Phase 1 tr
Foghorn Therapeutics has presented promising new preclinical data on its selective SMARCA2 inhibitor, FHD-909, which is advancing in a Phase 1 trial targeting SMARCA4 mutated cancers, particularly non-small cell lung cancer. The data highlights the anti-tumor synergy of FHD-909 in combination with other therapies, including pembrolizumab and several KRAS inhibitors. Additionally, Foghorn outlined its selective CBP and EP300 degrader programs that show potential in treating advanced cancers. An investor event is scheduled to discuss these updates further.
Read more →FHTXFoghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
Foghorn Therapeutics announced it will host a virtual investor event on April 29, 2025, to review updates on its pipeline, coinciding with the 2025 AACR Annual Meeting. The company will present new preclinical combination data for its candidate FHD-909, a selective SMARCA2 inhibitor targeting non-small cell lung cancer. Additional updates will include preclinical data from their Selective CBP and EP300 degrader programs. Investors can find more information and register for the event on the company's website.
Read more →FHTX▼ -5.9%on this news· ran to -17% by day 3
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
Foghorn Therapeutics announced new preclinical data for FHD-909, a selective SMARCA2 inhibitor, to be presented at the 2025 AACR Meeting. The data suggests promising efficacy in treating SMARCA4 mutated cancers, particularly non-small cell lung cancer, in combination with existing therapies. The company is also advancing its Selective CBP and EP300 degrader programs, showcasing their potential in hematological malignancies. The presentations will detail the ongoing Phase 1 trial progress and combination therapy strategies.
Read more →FHTXFoghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutate
Foghorn Therapeutics provided insights into its financial position and strategic outlook for 2024 and 2025. The company is actively enrolling patients in the Phase 1 trial for its novel SMARCA2 inhibitor, FHD-909, aimed at treating SMARCA4 mutated cancers. Additionally, positive developments around selective degradation of ARID1B signal promising results for future programs. The financial health of Foghorn is solid, with significant cash reserves that enable enduring operation and research efforts into 2027.
Read more →FHTXFoghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for SMARCA4 mutated cancers, with
Foghorn Therapeutics has made significant strides in its strategic objectives for 2025, focusing on the first-in-class oral SMARCA2 inhibitor, FHD-909, which is currently in Phase 1 trials for treating SMARCA4 mutated cancers, particularly targeting non-small cell lung cancer (NSCLC). The company anticipates presenting preclinical combination data with pembrolizumab and KRAS inhibitors at the AACR Annual Meeting in April 2025. Additionally, Foghorn has successfully advanced other programs aimed at selective degradation of ARID1B, CBP, and EP300, positioning itself strongly in the oncology field. With substantial financial resources, the company aims for impactful developments within the next year.
Read more →FHTXFoghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in co
Foghorn Therapeutics announced the discontinuation of the independent development of FHD-286 in combination with decitabine for treating relapsed and refractory AML, as the treatment's efficacy did not meet the company's development threshold. Despite observing objective clinical responses in a Phase 1 trial, the company will prioritize investments in its proprietary pipeline and collaborations, focusing on the selective SMARCA2 (BRM) inhibitor FHD-909. The company maintains a strong financial position with substantial cash reserves to support ongoing operations into 2027. Details regarding the Phase 1 trial results are expected to be reported at a medical conference in 2025.
Read more →FHTXFoghorn Therapeutics Provides Third Qu arter 2024 Financial and Corporate Update First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target populatio
Foghorn Therapeutics has provided an update for Q3 2024, highlighting the dosing of the first patient with FHD-909, a selective inhibitor for SMARCA4 mutated cancers, in a Phase 1 clinical trial. The company also anticipates data release from another trial for FHD-286 in acute myeloid leukemia by the end of 2024, as well as progress on IND-enabling studies for its Selective CBP degrader program. Despite a notable reduction in collaboration revenues, Foghorn maintains a robust financial position with significant cash reserves.
Read more →FHTXFoghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
Foghorn Therapeutics provided an update for Q3 2024, highlighting significant progress in their clinical trials and financial standing. The company dosed the first patient with FHD-909 in a Phase 1 trial targeting SMARCA4 mutated non-small cell lung cancer (NSCLC). Additionally, they expect to release topline results from the FHD-286 combination study in acute myeloid leukemia (AML) by the end of 2024. Despite a drop in collaboration revenue due to the conclusion of a Merck partnership, the firm maintains a robust cash position to support its ongoing and upcoming research.
Read more →FHTXFoghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Foghorn Therapeutics has commenced a Phase 1 trial for FHD-909, an oral SMARCA2 selective inhibitor, by dosing the first patient. Primarily targeting non-small cell lung cancer (NSCLC) with SMARCA4 mutations, this trial is significant for both Foghorn and their collaborator, Lilly. Preclinical data supports FHD-909's strong anti-tumor effects, and the drug's selectivity indicates potential for effective treatment strategies. The ongoing study aims to evaluate the safety and efficacy of FHD-909 in patients with advanced solid tumors harboring SMARCA4 alterations.
Read more →FHTX▼ -6.9%on this news
Foghorn Therapeutics to Participate in the BMO Oncology Summit
Foghorn Therapeutics Inc. will participate in the BMO Oncology Summit on October 8, 2024, in New York, NY. The company focuses on developing innovative medicines aimed at correcting abnormal gene expression to treat serious diseases. Their Gene Traffic Control platform promises to advance treatment options, particularly in oncology, and has a broad pipeline that may impact a wide array of diseases.
Read more →FHTX▼ -5.2%on this news
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Foghorn Therapeutics has announced the appointment of Dr. Anna Rivkin as Chief Business Officer effective September 3, 2024. With over two decades of experience in business development, Dr. Rivkin previously held leadership roles at Bristol Myers Squibb, managing high-value transactions across multiple therapeutic areas. Her expertise is expected to strengthen Foghorn's strategic alliances and business development efforts as the company seeks to realize the potential of its therapeutic pipeline.
Read more →FHTXFoghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
Foghorn Therapeutics Inc. (FHTX) will take part in the 2024 Wells Fargo Healthcare Conference and the Morgan Stanley 22nd Annual Global Healthcare Conference in September. Management, including CEO Adrian Gottschalk, will conduct one-on-one meetings to discuss the company's Gene Traffic Control platform aimed at treating serious diseases through gene expression correction. The conferences represent a significant occasion for the company to present its innovative pipeline focused on oncology.
Read more →FHTXFoghorn Therapeutics Provides Second Qu arter 2024 Financial and Corporate Update Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and or refractory AML patients, anticipated i
Foghorn Therapeutics provided a financial and corporate update, highlighting significant advancements in their clinical trials and financial health. They anticipate topline data for the FHD-286 Phase 1 trial in relapsed and refractory AML in Q4 2024. Additionally, dosing for the FHD-909 trial in NSCLC is expected to start in the second half of 2024, along with ongoing preparations for IND-enabling studies for their Selective CBP degrader program. The company successfully raised $110 million, extending their cash runway into 2027.
Read more →FHTXFoghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
Foghorn Therapeutics provided a financial and corporate update highlighting significant developments in their research pipeline. They expect to release topline data for FHD-286 in the fourth quarter of 2024, with positive indications for its potential in treating relapsed/refractory AML. Additionally, the company plans to initiate a Phase 1 trial for FHD-909, a first-in-class SMARCA2 selective inhibitor, and is advancing its Selective CBP degrader program. A recent financing round bolstered their financial position, extending their cash runway into 2027.
Read more →FHTXFoghorn Therapeutics to Participate in Upcoming Investor Conferences in June
Foghorn Therapeutics, a clinical-stage biotechnology company, announced its participation in two significant investor conferences in June 2024: the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Adrian Gottschalk will present at both events, showcasing management's focus on the company's innovative Gene Traffic Control platform aimed at treating serious diseases, particularly in oncology. The presentations will be complemented by one-on-one meetings, providing further engagement with potential investors.
Read more →FHTXForward Looking Statements 2 This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than st
Foghorn Therapeutics has presented forward-looking statements regarding its research and development activities, particularly its collaborations and progress in oncology therapeutics. The company is advancing several programs, including FHD-286 and FHD-909, which target a range of cancers, including AML and prostate cancer. However, the success of these initiatives is contingent upon overcoming regulatory hurdles and the challenges of developing selective inhibitors. The strategic partnership with Loxo@Lilly is seen as a key opportunity for growth in the competitive oncology landscape.
Read more →FHTXFoghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
Foghorn Therapeutics announced a registered direct offering that raised approximately $110 million, aimed at advancing its pipeline and supporting multiple data readouts. The funding boosts the company's balance sheet to $310 million in cash and equivalents, extending its cash runway into 2027. Notable investors in this round include BVF Partners and Deerfield Management, among others. Foghorn's focus remains on developing innovative therapies targeting serious diseases through its Gene Traffic Control Platform.
Read more →FHTX▲ +8.9%on this newsshared move
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
Foghorn Therapeutics Inc. has announced the pricing of a registered direct offering, selling 12,743,039 shares of common stock at $5.51 each, along with pre-funded warrants for an additional 7,220,794 shares. The offering is expected to close by May 22, 2024, aiming to raise approximately $110 million in gross proceeds. The net proceeds will support the company's preclinical and clinical programs, as well as general corporate expenses.
Read more →FHTXFoghorn Therapeutics Provides First Qu arter 2024 Financial and Corporate Update Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024 potential
Foghorn Therapeutics has provided its Q1 2024 financial and corporate update, highlighting significant progress in its clinical pipeline, particularly with the FHD-286 combination trial for AML and the IND submission for FHD-909, a selective BRM inhibitor. The company reported a strong cash position of $206.7 million, ensuring funding for continued development. Initial clinical data from the FHD-286 trial is expected in the second half of 2024, underscoring the promising trajectory of its novel therapeutics aimed at oncology.
Read more →FHTXFoghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
Foghorn Therapeutics has reported significant advancements in its clinical programs during the first quarter of 2024, including ongoing dose escalation in a Phase 1 trial of FHD-286 in AML and the IND submission for FHD-909, a novel BRM selective inhibitor. The company presented promising preclinical data at the AACR Annual Meeting and emphasized the strong financial position with $206.7 million in cash, providing a runway into mid-2026. Upcoming milestones include initial clinical data expected in the second half of 2024 for multiple programs.
Read more →FHTX▼ -5.6%on this news· ran to -17% by day 3
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE)
Foghorn Therapeutics has appointed Kristian Humer as its new Chief Financial Officer, effective April 16, 2024. Humer, who has over 14 years of experience in financial strategy in the life sciences, will play a critical role in guiding the company's financial leadership. His background includes top positions at Viridian Therapeutics and extensive experience on Wall Street, which will aid Foghorn as it prepares for significant milestones in drug development. Notably, clinical data for Foghorn's lead program, FHD-286, is anticipated in the second half of the year.
Read more →FHTXForward Looking Statements 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, y
Foghorn Therapeutics provides a pipeline update and a clinical progress overview at the AACR 2024 conference. Their lead candidate FHD-286, a dual BRM/BRG1 inhibitor for AML, is showing promising results in ongoing studies. The company also introduced FHD-909, a selective BRM inhibitor with strong preclinical efficacy. While their drug development efforts target complex chromatin biology and various cancers, challenges such as regulatory approvals and reliance on partnerships remain critical to their strategy.
Read more →FHTXFoghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics has presented promising preclinical data on its BRM selective inhibitor FHD-909, which demonstrated encouraging dose-dependent monotherapy activity in BRG1 mutated tumors. The company also reported significant progress in its selective CBP and EP300 degrader programs with robust anti-tumor effects and minimal side effects. An IND application for FHD-909 is expected to be filed in the second quarter of 2024, further validating Foghorn's drug discovery engine. The updates were announced at the 2024 American Association for Cancer Research Annual Meeting.
Read more →FHTXFoghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
Foghorn Therapeutics Inc. has announced its participation in the 23rd Annual Needham Virtual Healthcare Conference scheduled for April 11th, 2024. Adrian Gottschalk, the President and CEO, will present, showcasing Foghorn's Gene Traffic Control platform, which is aimed at transforming the treatment of serious diseases through the correction of abnormal gene expression. The event will include virtual one-on-one meetings, further enhancing investor engagement. A webcast of the discussion will be available for up to 30 days on Foghorn's website.
Read more →FHTXFoghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Foghorn Therapeutics Inc. announced plans to host a conference call and webcast on April 9, 2024, to discuss key programs in its pipeline, including updates on FHD-286 for acute myelogenous leukemia and new preclinical data for FHD-909. This event coincides with the 2024 AACR Annual Meeting and highlights the company's focus on pioneering a new class of medicines aimed at correcting abnormal gene expression. FHD-286 and FHD-909 demonstrate promising anti-tumor activity in preclinical studies, especially for cancers with specific mutations.
Read more →FHTXFoghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook Dose escalation in FHD-286 combination study in AML continues to progress clinical data anticipated in the second half of 2024 FHD-909, a
Foghorn Therapeutics has updated its financial outlook and strategic plans, reporting significant progression in their clinical studies including the FHD-286 combination therapy for AML. The company anticipates delivering crucial clinical data in the second half of 2024 while planning for multiple new INDs targeting various cancer indications over the next four years. Foghorn has also maintained a substantial cash reserve, allowing operations into 2026. Key collaborations, particularly with Lilly, are set to advance their pipeline of innovative oncology treatments.
Read more →FHTX▼ -5.9%on this newsshared move
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909
Foghorn Therapeutics is set to present new preclinical data at the 2024 AACR Annual Meeting, showcasing advances in several potential first-in-class medicines, including the FHD-909, a selective inhibitor of BRM. The data highlights the efficacy and safety of FHD-909 in mouse models of non-small cell lung cancer (NSCLC) and plans for an IND filing in Q2 2024. Additionally, the company will present results of its Selective CBP and EP300 degraders, focusing on their significant anti-tumor activity without the historically associated thrombocytopenia. These presentations at the conference aim to demonstrate Foghorn's progress in targeting the chromatin regulatory system for cancer treatment.
Read more →FHTX▲ +8.1%on this news
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
Foghorn Therapeutics, a biotech company focused on novel medicines for serious diseases, has announced its participation in Cowen's 44th Annual Health Care Conference scheduled for March 4-6, 2024. The company will present its Gene Traffic Control platform, which targets abnormal gene expression, particularly in oncology. Chief Medical Officer Alfonso Quintas-Cardama will present on March 4, and Foghorn will also engage in one-on-one meetings during the event.
Read more →FHTX▲ +55.4%on this news· ran to +99% by day 3
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
Foghorn Therapeutics announced that Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development, with an IND filing expected in Q2 2024. This drug targets BRG1 mutated non-small cell lung cancer (NSCLC) and aims to selectively inhibit BRM activity to promote tumor cell death. The collaboration with Lilly includes a shared commitment in developing this and additional oncology medicines, underpinned by promising preclinical results. Upcoming presentations of preclinical data are anticipated at scientific conferences.
Read more →FHTX▲ +6.4%on this news
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024 - FHD-286 combination study in AML continues to progress in the clinic with data anticipated in th
Foghorn Therapeutics has announced updates on its clinical pipeline and strategic goals for 2024. The company highlighted continued progress in the Phase 1 combination study of FHD-286 for AML and expects to present new preclinical data throughout the year. The collaboration with Loxo Lilly is advancing, and Foghorn aims to file at least six new INDs in the next four years, supported by a strong cash position. The upcoming data and strategic initiatives reflect Foghorn's commitment to developing innovative cancer therapies.
Read more →FHTX▼ -6.8%on this newsshared move
Foghorn Therapeutics Announces CFO Departure
Foghorn Therapeutics has announced that Chief Financial Officer Allan Reine will depart the company to pursue another opportunity. His last working day will be January 16, 2024. The company is currently searching for a successor to fill the position. The leadership at Foghorn, including CEO Adrian Gottschalk, expressed gratitude for Reine's contributions during his tenure.
Read more →FHTX▼ -6.8%on this newsshared move
Hans Vitzthum, LifeSci Advisors (Investors) hans lifesciadvisors.com
Foghorn Therapeutics has announced the departure of Chief Financial Officer Allan Reine, who will be leaving to pursue another opportunity. His final day with the company is set for January 16, 2024. The company has expressed gratitude for his contributions and is commencing a search for his replacement. Such leadership changes can lead to potential operational uncertainties for the company.
Read more →FHTX▲ +5.6%on this news
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
Foghorn Therapeutics Inc. has announced that clinical data from its Phase 1 study of FHD-286, a novel BRG1/BRM inhibitor, will be presented at the upcoming American Society of Hematology Annual Meeting. The study focuses on patients with advanced hematologic malignancies, specifically acute myeloid leukemia and myelodysplastic syndromes. Preliminary results demonstrate the drug's potential anti-tumor activity. The presentation will occur on December 11, 2023, in San Diego, California.
Read more →FHTX▲ +7.1%on this news
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update - First patient dosed in FHD-286 combination study in AML data expected in the second half of 2024 - Transitioned the BRM Selective inhibito
Foghorn Therapeutics has announced a positive update regarding its FHD-286 combination study for acute myeloid leukemia (AML), with the first patient successfully dosed. The company reported favorable preclinical data for its EP300 and CBP programs, showcasing potential therapeutic advancements. Financially, Foghorn holds $259.9 million in cash, providing support for operations through the first half of 2026. However, the firm also noted a net loss of $14.3 million for the quarter, raising concerns about profitability.
Read more →FHTXFoghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
Foghorn Therapeutics has announced its participation in two upcoming conferences, where it will present new data from its preclinical and clinical programs. The 6th Annual Targeted Protein Degradation Summit in Boston and the Connective Tissue Oncology Society Annual Meeting in Dublin will feature presentations from key executives including a keynote by Chief Scientific Officer Steve Bellon. Highlights include advancements in their selective EP300 and CBP degrader programs and the results from a Phase 1 study of FHD-609 in patients with advanced synovial sarcoma.
Read more →FHTXFoghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
Foghorn Therapeutics announced that clinical data from its Phase 1 study of FHD-286 in metastatic uveal melanoma will be presented at the upcoming ESMO Congress in Madrid. The compound is a novel BRG1/BRM inhibitor that has demonstrated anti-tumor activity in various pre-clinical studies. The presentation is scheduled for October 22, 2023, and will be conducted by Dr. Sapna Patel from MD Anderson Cancer Center. This highlights Foghorn's ongoing research efforts in targeting genetic regulatory systems for cancer treatment.
Read more →FHTXFoghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
Foghorn Therapeutics Inc. announced that it will present new clinical and pre-clinical data for its candidate drugs, particularly focusing on the BRG1/BRM inhibitor FHD-286 and its selective EP300 program, at the upcoming AACR-NCI-EORTC International Conference in Boston from October 11-15, 2023. The findings suggest FHD-286's efficacy as a differentiation agent in various tumor types, including acute myeloid leukemia and metastatic uveal melanoma. Furthermore, the company will showcase studies on the anti-tumor mechanism and potential applications of its other compounds like FHD-609, a BRD9 degrader.
Read more →FHTXFoghorn Therapeutics Announces Participation in Upcoming Investor Conferences
Foghorn Therapeutics Inc. has announced its participation in several investor conferences in September 2023, including events hosted by Wells Fargo, Morgan Stanley, and H.C. Wainwright. Management will engage in one-on-one meetings and a fireside chat to discuss the company's innovative Gene Traffic Control platform, which focuses on correcting abnormal gene expression to treat serious diseases. This participation reflects Foghorn's ongoing commitment to investor relations and its efforts to raise awareness about its potential to transform patient care.
Read more →FHTXFoghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
Foghorn Therapeutics has announced the dosing of the first patient in a Phase 1 study for FHD-286, which is being tested in combination with decitabine or cytarabine for relapsed and/or refractory acute myelogenous leukemia (AML). The company expressed confidence in FHD-286's potential after encouraging results from earlier monotherapy studies. The study aims to evaluate the safety and efficacy of the combination therapy and is expected to provide data in the second half of 2024. This advancement marks a significant step in addressing treatment options for AML patients.
Read more →FHTXDocument Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and or Refractory AML CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE)
Foghorn Therapeutics announced that the first patient has been dosed in a Phase 1 combination study of FHD-286 along with decitabine or cytarabine for relapsed and/or refractory acute myelogenous leukemia (AML). The study follows promising results from previous monotherapy phases, indicating the drug's potential to effectively differentiate treatment across diverse genomic backgrounds. The company expects to share results from this study in the second half of 2024, highlighting the ongoing need for improved therapeutic options in AML. The drug targets specific proteins involved in chromatin regulation, which are crucial in the development of various cancers, including AML.
Read more →FHTXFoghorn Therapeutics Announces Chief Medical Officer Succession CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE)
Foghorn Therapeutics has announced the appointment of Dr. Alfonso Quint s-Cardama as its new Chief Medical Officer, effective September 11, 2023. He will succeed Sam Agresta, who will retire from the position on the same date but will provide consulting services until early January 2024. Dr. Quint s-Cardama previously held leadership roles in clinical development at TCR2, GSK, and Novartis, bringing extensive experience in developing cancer therapies. His expertise is expected to enhance Foghorn's efforts in advancing its oncology pipeline.
Read more →FHTXFoghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update - Initiating FHD-286 combination study in AML in the third quarter of 2023 - Selective BRM, ARID1B, EP300, and CBP, targeting key regulator
Foghorn Therapeutics has provided an update on its financials and corporate advancements for the second quarter of 2023. The company plans to initiate a combination study of its drug FHD-286 in acute myeloid leukemia (AML) in the third quarter. Foghorn reported a cash position of $284.3 million, expected to fund operations through 2025, despite a net loss increase. The company is advancing multiple drug development programs and strengthening its collaborations with pharmaceutical partners.
Read more →FHTXFORWARD LOOKING STATEMENTS 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, y
Foghorn Therapeutics is advancing its research and development in oncology, focusing on chromatin biology to address significant patient needs through precision therapies. The company has secured substantial funding and collaborations with established oncology players like Lilly and Merck, enabling further development of their lead candidate, FHD-286. A phase 1 clinical trial for this drug in combination with decitabine is set to begin in Q3 2023, targeting relapsed and refractory AML patients. Despite these advances, challenges such as regulatory hurdles and clinical trial outcomes pose uncertainties for the company.
Read more →FHTXFoghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
Foghorn Therapeutics has announced the results of its Phase 1 study for FHD-286 in metastatic uveal melanoma, reporting a favorable safety profile and observed clinical activity, including one patient achieving a partial response. However, the company does not intend to further pursue this indication and is shifting its focus to a combination study in relapsed/refractory acute myeloid leukemia (AML) scheduled for the third quarter of 2023. The study evaluated 73 patients, with several experiencing stable disease and some showing tumor reductions.
Read more →FHTXFoghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
Foghorn Therapeutics has announced that the FDA has lifted the clinical hold on its Phase 1 study of FHD-286, a potential treatment for relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company plans to initiate a Phase 1 study combining FHD-286 with decitabine or cytarabine in Q3 2023, based on promising clinical and pre-clinical data. Despite the advancements, concerns regarding differentiation syndrome—previously linked to FHD-286—persist, as the company continues its focus on patient safety and efficacy in highly challenging patient populations.
Read more →FHTX▼ -10.2%on this news
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update - Data from Phase 1 dose escalation study of FHD-286, a BRG1 BRM inhibitor, in metastatic uveal melanoma expected in the second quarter of 2
Foghorn Therapeutics reported financial results for Q1 2023, highlighting a cash position of $316 million that supports operations through 2025. The company anticipates upcoming data from its ongoing Phase 1 study of FHD-286, a candidate for metastatic uveal melanoma. However, the program faces a clinical hold in AML and MDS, impacting its development timeline. Foghorn's collaborations with major pharmaceutical firms reinforce the potential of its innovative oncology programs.
Read more →FHTX▼ -5%on this news
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
Foghorn Therapeutics Inc. will participate in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at the Nasdaq Headquarters in New York City. The company, known for its Gene Traffic Control platform, is focused on innovating treatments for serious diseases, particularly in oncology. CEO Adrian Gottschalk will present during the event, which will also be available as a webcast for later viewing.
Read more →FHTX▼ -7.9%on this newsshared move
Foghorn Therapeutics Provides an Update on FHD-609 CAMBRIDGE, Mass.--(GLOBE NEWSWIRE)
Foghorn Therapeutics has provided an update on its FHD-609 program, which is focused on treating synovial sarcoma and SMARCB1-deleted tumors. The company has paused enrollment in the study after a serious adverse event, specifically a grade 4 QTc prolongation in a patient at the second highest dose. While the FDA has placed the study on partial clinical hold, patients currently benefiting from the treatment have been allowed to continue their dosing. Foghorn will not pursue a dose expansion study at this time.
Read more →FHTXFoghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting
Foghorn Therapeutics announced it will present preclinical data for its protein degrader programs at the 2023 AACR Annual Meeting. Key highlights include the potential treatment uses of FHD-286, a selective inhibitor targeting BRG1 and BRM, which has shown promise in acute myeloid leukemia models. The company will also outline its Selective EP300 and CBP programs, aimed at addressing cancers with significant unmet needs. Despite this progress, the Phase 1 clinical trial for AML and MDS is currently on full clinical hold.
Read more →FHTXFoghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
Foghorn Therapeutics announced its participation at the 18th Annual Drug Discovery Chemistry Meeting, where it will highlight preclinical data on its innovative treatments targeting transcription factors and protein degradation. The company will focus on presenting its first-in-class compound FHD-609, currently in Phase 1 clinical trials for synovial sarcoma and SMARCB1-loss tumors. Significant findings related to these areas will be shared, with initial efficacy data anticipated in mid-2023.
Read more →FHTXFoghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
Foghorn Therapeutics has provided a comprehensive update on its strategic priorities for 2023 and its achievements for 2022. The company is advancing multiple clinical trials, including FHD-286 for metastatic uveal melanoma and FHD-609 for synovial sarcoma, with initial data anticipated in the coming months. Despite a strong cash position and a promising pipeline, the company faces challenges, notably a clinical hold from the FDA affecting one of its programs. Foghorn is poised for growth with potential new IND applications in the next four years and strategic collaborations in place.
Read more →FHTXFoghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
Foghorn Therapeutics Inc. is set to participate in Cowen’s 43rd Annual Health Care Conference from March 6-8, 2023, in Boston, MA. The company will be represented by CEO Adrian Gottschalk during a leukemia panel scheduled for March 8 at 12:50 p.m. ET. This participation highlights Foghorn's commitment to addressing serious diseases through its Gene Traffic Control platform, which focuses on correcting abnormal gene expressions.
Read more →FHTXFoghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023 - Phase 1 dose escalation study of FHD-286, a BRG1 BRM inhibitor, in metastatic uveal melanoma continues to
Foghorn Therapeutics has announced significant clinical advancements and strategic objectives for 2023, highlighting ongoing studies of its drug candidates FHD-286 and FHD-609. Initial efficacy and safety data for FHD-286 in metastatic uveal melanoma and FHD-609 in synovial sarcoma are expected in mid-2023. Despite a recent FDA clinical hold on FHD-286 for acute myelogenous leukemia and myelodysplastic syndrome, the company aims to file at least six new INDs in the next four years based on their robust precision medicine platform. As of September 30, 2022, the company reported $373.5 million in cash reserves, providing a significant runway for development.
Read more →FHTX▼ -6.1%on this news
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new preclinical data
Read more →FHTXFoghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Adrian Gottschalk, Pr
Read more →FHTXFoghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the Company will share pre
Read more →FHTX▼ -8.5%on this newsshared move
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for i
Read more →FHTXFoghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update - FHD-286 Phase 1 dose escalation study in metastatic uveal melanoma continues to progress with initial data expected in the first half of 2
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update -FHD-286 Phase 1 dose escalation study in metastatic uveal melanoma continues to progress with initial data expected in the first half of 2023 -FHD-609 Phase 1 pharmacodynamic data shows degradation
Read more →FHTXFoghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Thomas Lyn
Read more →FHTXFoghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
Initial Phase 1 data of FHD-609 show degradation of BRD9 in on-treatment metastatic tumor synovial sarcoma biopsies New preclinical data demonstrate FHD-609 is highly selective, with no off-target IMiD neosubstrate degradation activity Newly announced Selective CBP degrader pro
Read more →FHTXFoghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will pres
Read more →FHTX▲ +7.2%on this news
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will par
Read more →FHTX▼ -6.6%on this newsshared move
Document Foghorn Therapeutics Announces Change to Board of Directors Foghorn Congratulates Co-Founder Cigall Kadoch on HHMI Appointment and Change in Role to Scientific Advisor to the Board CAMBRIDGE, Mass. -- (GLOBE NEW
Foghorn Therapeutics Announces Change to Board of Directors Foghorn Congratulates Co-Founder Cigall Kadoch on HHMI Appointment and Change in Role to Scientific Advisor to the Board CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE) -- August 31, 2022 -- Foghorn Therapeutics Inc. (Nasdaq FHTX
Read more →FHTX▼ -6.6%on this newsshared move
Foghorn Therapeutics Announces Change to Board of Directors
CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Cigall Kadoch, Ph.D.,
Read more →FHTX▼ -25.1%on this news
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed Refractory AML MDS CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE)
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed Refractory AML MDS CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE) - August 23, 2022 -- Foghorn Therapeutics Inc. (Nasdaq FHTX), a clinical stage biotechnology company pioneering a new class of medicines that
Read more →FHTXFoghorn Therapeutics Appoints Lynne Parshall to its Board of Directors
CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced t
Read more →FHTXFoghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update -FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol working to resolve partial clinical hold in AML and MDS -On track to report initial Phase 1 cl
Read more →FHTXFoghorn Therapeutics Announces Upcoming Investor Conference Participation
CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced manag
Read more →FHTXThis presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looki
Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases May 2022 Exhibit 99.1 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presenta
Read more →FHTXFoghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced th
Read more →FHTX▼ -8.6%on this news
Foghorn Therapeutics Provides First Quarter 2022 Corporate Update - Foghorn continues to advance three phase 1 studies through selectively targeting the chromatin regulatory system both FHD-286 and FHD-609 continue to do
Foghorn Therapeutics Provides First Quarter 2022 Corporate Update -Foghorn continues to advance three phase 1 studies through selectively targeting the chromatin regulatory system both FHD-286 and FHD-609 continue to dose escalate and enroll patients with initial clinical data e
Read more →FHTXFoghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting
CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced pre
Read more →FHTXFoghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the
Read more →FHTX▲ +10.8%on this news· ran to +22% by day 3
Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day
CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced tha
Read more →FHTXFoghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook - Initial clinical data for FHD-286 expected in H1'22 and FHD-609 as early as H1'22 - Advancing broad therapeutic pipeline of oncology progra
Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook -Initial clinical data for FHD-286 expected in H1'22 and FHD-609 as early as H1'22 -Advancing broad therapeutic pipeline of oncology programs including protein degraders, enzymatic inhibitors and tra
Read more →FHTXFoghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that
Read more →FHTXFoghorn Therapeutics Announces Chief Scientific Officer Succession
CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced Steven Bel
Read more →FHTXFoghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference
CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that
Read more →FHTX▲ +55%on this news
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control Platform - Establishes co-development and co-commercialization agreement on Foghorn's selecti
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic -Establishes co-development and co-commercialization agreement on Foghorn's selective BRM program and an additional undisclosed program -Collaboration includes
Read more →FHTXFoghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced th
Read more →FHTXFoghorn Therapeutics Provides Third Quarter 2021 Corporate Update
-- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma -- Continue to enroll patients in phase 1 clinical trials of FHD-286, an inhibitor of
Read more →FHTXDocument Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update -- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being
Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update -- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma -- Continue to enro
Read more →FHTXFoghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that
Read more →FHTXFoghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced t
Read more →FHTXDocument Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this " Amendment ") is entered into as of
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this "Amendment") is entered into as of August 30, 2021 (the "Second Amendment Date"), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office locat
Read more →FHTXDocument Foghorn Therapeutics Announces First Patient Dosed in First-in- Human Clinical Trial of FHD-609 FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9 Foghorn's first protein degrader
Foghorn Therapeutics Announces First Patient Dosed in First-in- Human Clinical Trial of FHD-609 FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9 Foghorn's first protein degrader program to enter the clinic continues pre-clinical work on other p
Read more →FHTXFoghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609
FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9 Foghorn’s first protein degrader program to enter the clinic; continues pre-clinical work on other protein degrader programs for broad range of cancers Significant unmet need in synovial sarcoma w
Read more →FHTXDocument Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update -- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1 BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory
Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update -- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1 BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML) -- IND Clearance for FHD-609 Received
Read more →FHTXFoghorn Therapeutics Provides Second Quarter 2021 Corporate Update
-- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML) -- IND Clearance for FHD-609 Received; Sites for Phase 1 Study in Synovial Sarcoma Initiated -- Continue
Read more →FHTXFoghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that
Read more →FHTXjuly2021foghorninv Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases July 2021 Disclaimer, Confidentiality, and Forward-Looking StatementsThis presenta
Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases July 2021 Disclaimer, Confidentiality, and Forward-Looking StatementsThis presentation contains forward-looking statements. All statements other than statements
Read more →FHTXFoghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021
CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that
Read more →FHTXfinv2 9:00 -9:10 a.m. 9:10 -9:25 a.m. 9:25 -9:45 a.m. 9:45 -10:05 a.m. 10:05 -10:20 a.m. 10:20 -10:30 a.m. 10:30 -10:45 a.m. 10:45 -11 :00 a.m. FOGHORN' THlaRAPlaVTICS Welcome and Introduction Adrian Gottschalk, P reside
9:00 -9:10 a.m. 9:10 -9:25 a.m. 9:25 -9:45 a.m. 9:45 -10:05 a.m. 10:05 -10:20 a.m. 10:20 -10:30 a.m. 10:30 -10:45 a.m. 10:45 -11 :00 a.m. FOGHORN' THlaRAPlaVTICS Welcome and Introduction Adrian Gottschalk, P resident and CEO, Foghorn Therapeutics Chromatin Regulatory System -Dise
Read more →FHTXFoghorn Therapeutics to Host Research & Development Day Webinar on June 15th
CAMBRIDGE, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that
Read more →FHTXFoghorn Therapeutics to Present in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that A
Read more →FHTXFoghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286
- First clinical candidate of a new class of therapeutics directly targeting the chromatin regulatory system - FHD-286 is a highly potent, selective, allosteric, oral, small molecule inhibitor of BRG1/BRM CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics I
Read more →FHTXFoghorn Therapeutics Provides Corporate Update
- Received IND clearance for FHD-609, a targeted protein degrader, which is being developed for the treatment of synovial sarcoma - Continued to advance broad therapeutic pipeline targeting the chromatin regulatory system CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Fogho
Read more →FHTXFoghorn Therapeutics Appoints Ian Smith to its Board of Directors
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the
Read more →FHTXFoghorn Therapeutics Provides Corporate Update - FHD-286 Phase 1 data anticipated as early as year-end 2021 - FHD-609 IND submission on track for the second quarter 2021 - Continued advancement of broad therapeutic pipel
Foghorn Therapeutics Provides Corporate Update - FHD-286 Phase 1 data anticipated as early as year-end - FHD-609 IND submission on track for the second quarter 2021 - Continued advancement of broad therapeutic pipeline targeting the chromatin regulatory system CAMBRIDGE, Mass
Read more →FHTXFoghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021
CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that
Read more →FHTXFoghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that
Read more →FHTXTargeting the Chromatin Regulatory System A Product Platform with Potential to Impact Millions of Patients
Platform with Potential to Impact Millions of Patients February 16, 2021Exhibit 99.1 Targeting the Chromatin Regulatory System A Product Platform with Potential to Impact Millions of Patients February 16, 2021 Precision Oncology: Novel Biology with Breadth and Depth Large Market
Read more →FHTXFoghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update - Well positioned to advance broad pipeline with recent completion of IPO and Merck collaboration - On track to submit an
Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update - Well positioned to advance broad pipeline with recent completion of IPO and Merck collaboration - On track to submit an IND for FHD-286 by year end 2020 and for FHD-609 during t
Read more →FHTXFoghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the a
Read more →FHTXFoghorn Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the p
Read more →Competitive Position
How FHTX ranks across every disease it competes inCompetitive Position is a premium feature
See how FHTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial